MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Fisher & Paykel come out on top in German patent spat with ResMed

Fisher & Paykel come out on top in German patent spat with ResMed

By

ResMed, Fisher & PaykelFisher & Paykel Healthcare (NZE:FPH) said last Friday that a German court overturned preliminary injunctions granted to ResMed (NYSE:RMD) in a patent infringement case filed in August.

With the overturned injunction, Fisher & Paykel said it has resumed sales of its Simplus full face mask, Eson nasal mask and Eson 2, which San Diego-based ResMed claimed infringed on its patents.

Fisher & Paykel shares have jumped on the news, rising 6.2% to close at $8.72. The company had previously lost more than 21% since ResMed filed legal action on August 18.

“We are pleased with the outcome of the first two hearings in these patent dispute proceedings and we remain confident in regards to future proceedings,” Fisher & Paykel CEO Lewis Gradon said in a press release.

Fisher & Paykel initiated the hostilities with an August 15 lawsuit in a California federal court, alleging that ResMed’s AirSense 10 and AirCurve 10 flow generators, ClimateLineAir heated air tubing and Swift mask line infringe 11 of its patents. The Auckland, N.Z.-based company moved to withdraw that suit the next day, but reserved the right to sue again, according to documents filed with the U.S. District Court for Central California.

On August 18, ResMed announced a responding barrage, with actions filed in another California federal court, plus Germany, New Zealand and the ITC. The lawsuit filed in the U.S. District Court for Southern California alleges that Fisher & Paykel’s Simplus full face mask, Eson nasal mask and Eson 2 nasal mask infringe 4 of ResMed’s patents and asks the court to invalidate its Down Under rival’s patents, find that it’s not infringing, or both.

ResMed sought an injunction from the ITC banning Fisher & Paykel from importing the allegedly infringing devices and claimed a win in Germany. The Munich District Court granted ResMed’s bid for a pair of preliminary injunctions stopping the sale of the Simplus, Eson and Eson 2 devices. In New Zealand the company is seekingto halt the manufacture and exportation of the devices, ResMed said.

Material from Reuters was used in this report.

In case you missed it

RSS From Medical Design & Outsourcing

  • B. Braun receives FDA approval for Florida pharmaceutical manufacturing plant
    B. Braun Medical announced today that it received final approval from the FDA for its new pharmaceutical manufacturing plant. Bethlehem, Pennsylvania-based B. Braun’s Daytona Beach, Florida-based plant will produce 0.9% sodium chloride for injection available in B. Braun’s Excel Plus IV bags in 1,000 mL and 500 mL sizes. Get the full story at our… […]
  • 3D Printing: Making products better, faster, and more affordable
    With help from HP’s Multi Jet Fusion 3D printing technology, Biotec produces improved parts for its medical devices in less time and at a lower cost. Download this white paper… The post 3D Printing: Making products better, faster, and more affordable appeared first on Medical Design and Outsourcing.
  • Eli Lilly to build $1B manufacturing facility for injectable products, devices in North Carolina
    Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1 billion to create a new manufacturing site in North Carolina. Indianapolis-based Eli Lilly’s new facility, which it expects to bring with it nearly 600 jobs in Concord, North Carolina, will manufacture parenteral (injectable) products and devices while increasing the company’s manufacturing capacity. Get… […]
  • How Bigfoot Biomedical plans to take diabetes management forward
    For close to 20 years, Jeffrey Brewer has focused on finding ways to support insulin delivery and manage diabetes. Bryan Mazlish was the first person in the world to hack into an insulin pump and continuous glucose monitor (CGM) and enable a do-it-yourself closed-loop insulin dosing system, Brewer told Drug Delivery Business News. “It turned… […]
  • Edwards Lifesciences misses on Q4 earnings as omicron hammers hospitals
    Edwards Lifesciences (NYSE:EW) posted fourth-quarter results that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022. The Irvine, California-based heart device company yesterday evening reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months ended Dec. 31, 2021,… […]
  • How Phillips-Medisize helped Sotech Health develop a breath analyzer for COVID-19
    Medtech contract manufacturing giant Phillips-Medisize used its human-factors product design expertise to help startup Sotech Health create what the companies claim is a breath sensor system that can detect COVID-19 in less than 30 seconds. Dallas-based Sotech Health has submitted the device to the FDA for an emergency use authorization. It’s also seeking regulatory nods… […]
  • Carbon introduces next-gen 3D printers
    Carbon today announced its next-gen M-Series 3D printers based on DLS technology. The new M3 and the M3 Max printers boast faster printing, a more straightforward print experience, expanded design space and a more consistent surface finish, according to Carbon. Carbon said a 4K light engine enables a doubling of the build area with the… […]
  • Philips launches at-home, 12-lead ECG for clinical trials
    Royal Philips (NYSE: PHG, AEX: PHIA) announced today that it is expanding its remote cardiac monitoring portfolio with a patch-based, clinical-grade ECG. The new at-home electrocardiogram monitors could reduce the need for site visits during clinical trials, according to the Dutch medtech giant. At-home ECG is a hot space: iRhythm Technologies CEO Quentin Blackford recently… […]
  • TE Connectivity beats the Street in Q1
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus forecast on Wall Street. The Schaffhausen, Switzerland–based company provides connectivity and sensor solutions for a broad range of industries, including medtech. The company reported profits of $566 million — or $1.72 per share — on sales of $3.8 billion for the fiscal quarter ended… […]
  • Element Materials Technology acquired by Temasek
    Element Materials Technology this week announced that it was acquired by Bridgepoint’s Temasek for an undisclosed amount. Singapore-based Temasek has been a majority shareholder in Element since 2019. Element expects to accelerate its growth and build stronger positions in end-markets like life sciences and connected technologies, according to the company. “The acquisition of Element by… […]
  • FDA approves Medtronic’s spinal cord stimulation for chronic pain from diabetic neuropathy
    Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain. The approval covers the Intellis rechargeable neurostimulator and the Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy. Get the full story at our sister site, MassDevice. The post FDA approves Medtronic’s spinal cord stimulation […]